 |
|
|
| Internet Search |
|
Stock Search |
|
|
|
|
|
INSITE VISION INC, (ISV) Stock Rating Learn More
| Our Overall Rating on INSITE VISION INC, ISV is Not Available | | InSite Vision Incorporated engages in the development of genetically-based technology for the diagnosis, prognosis, and management of glaucoma, as well as ophthalmic pharmaceutical products based on its proprietary DuraSite eyedrop-based drug delivery technology. In addition, it has a retinal program that includes both a therapeutic agent and a retinal drug delivery technology. The company focuses its research and development, and commercial efforts on ISV-403, a DuraSite formulation of fluoroquinolone; ISV-401, a DuraSite formulation of azithromycin, an antibiotic; and OcuGene glaucoma genetic test based on its ISV-900 technology. The company has collaborative agreements with Bausch and Lomb Incorporated; CIBA Vision Ophthalmics; SSP Co., Ltd.; Global Damon Pharm and Kukje Pharma Ind. Co., Ltd.; Columbia Laboratories, Inc.; and Societa Industria Farmaceutica Italiana. InSite Vision is based in Alameda, California. | | Our Not Available Rating on ISV was issued on 11/21/2008 |
INSITE VISION INC Technical Rating
|
|
|
|
